Skip to main content
Pharvaris N.V. logo

Pharvaris N.V. — Investor Relations & Filings

Ticker · PHVS ISIN · NL00150005Y4 LEI · 9845003BE146D3B75D32 US Manufacturing
Filings indexed 210 across all filing types
Latest filing 2024-08-19 Regulatory Filings
Country NL Netherlands
Listing US PHVS

About Pharvaris N.V.

https://pharvaris.com/

Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare, bradykinin-mediated diseases, with a primary focus on hereditary angioedema (HAE). The company is advancing a pipeline of novel, oral bradykinin B2 receptor antagonists. Its lead product candidate, deucrictibant, is in pivotal Phase 3 studies for both the on-demand (acute) and prophylactic (preventative) treatment of HAE attacks. Pharvaris aims to provide patients with an effective, well-tolerated oral therapy as a convenient alternative to injectable treatments.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-08-19 English
Regulatory Filings 2024
Regulatory Filings
2024-08-19 English
Regulatory Filings 2024
Regulatory Filings
2024-08-16 English
Regulatory Filings 2024
Regulatory Filings
2024-08-15 English
Regulatory Filings 2024
Regulatory Filings
2024-08-14 English
6-K
Foreign Filer Report
2024-08-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.